Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cost-Effectiveness Analysis of Ivabradine in Treatment of Patients With Heart Failure in Iran Publisher Pubmed



Taheri S1 ; Heidari E2 ; Aivazi MA1 ; Shamsbeyranvand M3 ; Varmaghani M4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmacoeconomics and Pharma Management, School of pharmacy, Shahid Beheshti University of Medical Science Students' Research Committee, Shahid Beheshti University of Medical Science, Iran
  2. 2. Non-Communicable Disease Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Iran
  3. 3. Dezful University of Medical Sciences, Non-Communicable Disease Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Iran
  4. 4. Social Determinants of Health Research Center, Mashhad University of Medical Sciences Non-Communicable Disease Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Iran

Source: International Journal of Technology Assessment in Health Care Published:2018


Abstract

Objectives: This study aimed to assess the cost-effectiveness of ivabradine plus standard of care (SoC) in comparison with current SoC alone from the Iranian payer perspective. Methods: A cohort-based Markov model was developed to assess the incremental cost-effectiveness ratio (ICER) over a 10-year time horizon in a cohort of 1,000 patients. The baseline transition probabilities between New York Heart Association (NYHA), mortality rate, and hospitalization rate were extracted from the literature. The effect of ivabradine on mortality, hospitalization, and NYHA improvement or worsening were retrieved from the SHIFT study. The effectiveness was measured as quality-adjusted life-years (QALYs) using the utility values derived from Iranian Heart Failure Quality of Life study. Direct medical costs were obtained from hospital records and national tariffs. Deterministic and probabilistic sensitivity analyses were conducted to show the robustness of the model. Results: Ivabradine therapy was associated with an incremental cost per QALY of USD $5,437 (incremental cost of USD $2,207 and QALYs gained 0.41) versus SoC. The probabilistic sensitivity analysis showed that ivabradine is expected to have a 60 percent chance of being cost-effective accepting a threshold of USD $6,550 per QALY. Furthermore, deterministic sensitivity analysis indicated that the model is sensitive to the ivabradine drug acquisition cost. Conclusions: The cost-effectiveness model suggested that the addition of ivabradine to SoC therapy was associated with improved clinical outcomes along with increased costs. The analysis indicates that the clinical benefit of ivabradine can be achieved at a reasonable cost in eligible heart failure patients with sinus rhythm and a baseline heart rate ≥ 75 beats per minute (bpm). © 2018 Cambridge University Press.
Related Docs
1. Salivary B-Type Natriuretic Peptide: A New Method for Heart Failure Diagnosis and Follow-Up, Kardiologia Polska (2017)
2. Heart Failure Care in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis, PLoS Medicine (2015)
3. Self-Monitoring by Traffic Light Color Coding Versus Usual Care on Outcomes of Patients With Heart Failure Reduced Ejection Fraction: Protocol for a Randomized Controlled Trial, JMIR Research Protocols (2018)
Experts (# of related papers)
View all Related Experts
Shahrzad Ghiyasvandian (1)
Farshad Farzadfar (1)